Inventor · disambiguated record
József Répási
Also filed as: REPASI JOZSEF · REPASI JOZSEF JOZSEF REPASI · RÉPÁSI JÓZSEF
5 granted patents·4 pending applications·3 citations·filing 2005–2023
68Inventor score
Files withPRINTNET KERESKEDELMI ES SZOLGALTATO KFT3GALIMEDIX THERAPEUTICS INC2ABEL ULRICH1MEDICHEM SA1REPASI JOZSEF1
Top patents by PatentIndex Score
9 records- 0182US11845758B2Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoformsPRINTNET KERESKEDELMI ES SZOLGALTATO KFT·Filed 2023·Granted Dec 19, 2023·1 cites·27 claims
- 0275US11891455B2Polymorph form of (r)-2-[2-amino-3-(indol-3-yl)propionylamino]-2- methylpropionic acid and uses thereofGALIMEDIX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·1 cites·14 claims
- 0374US12421243B2Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoformsPRINTNET KERESKEDELMI ES SZOLGALTATO KFT·Filed 2023·Granted Sep 23, 2025·0 cites·12 claims
- 0466US11746112B2Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoformsPRINTNET KERESKEDELMI ES SZOLGALTATO KFT·Filed 2019·Granted Sep 5, 2023·1 cites·23 claims
- 0545US2023242483A1Crystalline forms of solvates of tryptophan derivatives, compositions comprising them and uses thereofGALIMEDIX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0641US8664397B2Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylaseREPASI JOZSEF·Filed 2005·Granted Mar 4, 2014·0 cites·9 claims
- 0738US2011295037A1Processes for preparing cinacalcet hydrochloride and polymorphic forms thereofSZEKERES TIBOR·Filed 2007·Application pending·0 cites
- 0838US2010267988A1Processes for preparing intermediate compounds useful for the preparation of cinacalcetMEDICHEM SA·Filed 2007·Application pending·0 cites
- 0935US2019047933A1Process for the synthesis of (2e, 4e, 6z, 8e)-8-(3,4-dihydronaphthalen-1(2h)-ylidene)-3,7-dimethylocta-2, 4, 6-trienoic acidABEL ULRICH·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →